Compare KLAR & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KLAR | APGE |
|---|---|---|
| Founded | 2005 | 2022 |
| Country | United Kingdom | United States |
| Employees | 2831 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.7B |
| IPO Year | N/A | 2023 |
| Metric | KLAR | APGE |
|---|---|---|
| Price | $12.97 | $86.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $39.57 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 5.7M | 1.1M |
| Earning Date | 05-18-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.75 | N/A |
| Revenue Next Year | $19.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.06 | $31.21 |
| 52 Week High | $47.48 | $87.00 |
| Indicator | KLAR | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 66.36 |
| Support Level | $12.28 | $73.06 |
| Resistance Level | $16.78 | N/A |
| Average True Range (ATR) | 0.78 | 4.44 |
| MACD | 0.25 | 0.76 |
| Stochastic Oscillator | 44.60 | 89.83 |
Klarna Group PLC is a technology-driven payments company, with operations spanning multiple countries. It connects consumers and merchants with comprehensive payment solutions and tailored advertising solutions, both online and offline. Its payment solutions provide consumers with more control and flexibility over their payments. It is a digital bank and flexible payments provider building the next-generation AI-powered commerce network.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.